By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Aztreonam (monograph) > Aztreonam (monograph) Side Effects
Drugs

Aztreonam Side Effects

Summary

Commonly reported side effects of aztreonam include: fever. Continue reading for a comprehensive list of adverse effects.

Applies to aztreonam: inhalation powder for solution. Other dosage forms:

  • powder for solution

Serious side effects of Aztreonam

Along with its needed effects, aztreonam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking aztreonam:

More common

  • Chest discomfort
  • cough
  • difficulty with breathing or troubled breathing
  • fever

Less common

  • Noisy breathing
  • shortness of breath
  • tightness in the chest

Other side effects of Aztreonam

Some side effects of aztreonam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Abdominal or stomach pain
  • sore throat
  • stuffy nose
  • vomiting

Less common

  • Rash

For Healthcare Professionals

Applies to aztreonam: inhalation powder for reconstitution, injectable powder for injection, intravenous solution.

General

Aztreonam for injection was generally well tolerated. The overall incidence of systemic side effects was about 1% to 1.3%.[Ref]

Respiratory

Aztreonam for inhalation:

Very common (10% or more): Cough (54%), nasal congestion (16%), wheezing (16%)

Common (1% to 10%): Bronchospasm (3%)

Postmarketing reports: Dyspnea

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Wheezing, dyspnea, chest pain, sneezing, nasal congestion[Ref]

Other

Aztreonam for inhalation:

Very common (10% or more): Pyrexia (13%), pharyngolaryngeal pain (12%)

Common (1% to 10%): Chest discomfort (8%), abdominal pain (7%)

Aztreonam for injection:

Common (1% to 10%): Superinfection (up to 10%)

Uncommon (0.1% to 1%): Less than 1%: Weakness, fever, malaise, flushing[Ref]

Superinfection has been reported in up to 10% of patients during aztreonam therapy and was usually due to enterococcus or staphylococcus.[Ref]

Gastrointestinal

Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.[Ref]

Aztreonam for inhalation:

Common (1% to 10%): Vomiting (6%)

Aztreonam for injection:

Common (1% to 10%): 1% to 1.3%: Nausea, vomiting, diarrhea

Uncommon (0.1% to 1%): Less than 1%: Abdominal cramps, mouth ulcer, altered taste, numb tongue, halitosis

Rare (less than 0.1%): Clostridium difficile associated diarrhea, pseudomembranous colitis, gastrointestinal bleeding[Ref]

Dermatologic

Aztreonam for inhalation:

Common (1% to 10%): Rash (2%)

Aztreonam for injection:

Common (1% to 10%): Rash (1% to 1.3%)

Uncommon (0.1% to 1%): Less than 1%: Toxic epidermal necrolysis, purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis[Ref]

Toxic epidermal necrolysis associated with aztreonam has been reported in very ill patients on many other medications, making implication of aztreonam difficult.[Ref]

Local

Aztreonam for injection:

Common (1% to 10%): Discomfort/swelling at the injection site after intramuscular administration (2.4%), phlebitis/thrombophlebitis after intravenous administration (1.9%)[Ref]

Hypersensitivity

Aztreonam for inhalation:

Frequency not reported: Allergic reaction (with facial rash, facial swelling, throat tightness)

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Anaphylaxis, angioedema, bronchospasm

Rare (less than 0.1%): Maculopapular eruption (at least 1 case)[Ref]

A 57-year-old male developed a widespread maculopapular eruption two hours after receiving aztreonam. Corticosteroids and antihistamines were needed to control the reaction which disappeared after 8 days. The patient also showed cross-reactivity to ceftazidime which shares the same side chain as aztreonam.[Ref]

Hematologic

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis

Frequency not reported: Increased prothrombin time, increased partial thromboplastin time, positive Coombs' test[Ref]

A case of myelosuppression associated with aztreonam has been reported, but because many other drugs were administered and because the patient was bacteremic, implication of aztreonam as the causative agent was difficult.

In vitro studies have shown that aztreonam may inhibit ADP-induced platelet aggregation at high concentrations. Clinically, therapeutic doses of aztreonam have not been associated with bleeding problems.[Ref]

Hepatic

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Hepatitis, jaundice, signs or symptoms of hepatobiliary dysfunction

Frequency not reported: Elevated AST, elevated ALT, elevated alkaline phosphatase[Ref]

Cardiovascular

Aztreonam for injection:

Uncommon (0.1% to 1%): Hypotension (less than 1%), transient electrocardiogram changes (ventricular bigeminy, premature ventricular contractions; less than 1%)[Ref]

Nervous system

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Seizure, headache, confusion, vertigo, paresthesia, insomnia, dizziness, tinnitus[Ref]

Musculoskeletal

Aztreonam for inhalation:

Postmarketing reports: Arthralgia, joint swelling

Aztreonam for injection:

Uncommon (0.1% to 1%): Muscular aches (less than 1%)[Ref]

Renal

Acute interstitial nephritis associated with aztreonam has been reported in a very ill patient receiving many other medications.[Ref]

Aztreonam for injection:

Rare (less than 0.1%): Acute interstitial nephritis (at least 1 case)

Frequency not reported: Increased serum creatinine[Ref]

Genitourinary

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Vaginal candidiasis, vaginitis, breast tenderness[Ref]

Ocular

Aztreonam for injection:

Uncommon (0.1% to 1%): Diplopia (less than 1%)[Ref]

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by